BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1004 related articles for article (PubMed ID: 27121414)

  • 1. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions.
    Lubeseder-Martellato C; Alexandrow K; Hidalgo-Sastre A; Heid I; Boos SL; Briel T; Schmid RM; Siveke JT
    EBioMedicine; 2017 Feb; 15():90-99. PubMed ID: 28057438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
    Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
    Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas.
    Chen NM; Singh G; Koenig A; Liou GY; Storz P; Zhang JS; Regul L; Nagarajan S; Kühnemuth B; Johnsen SA; Hebrok M; Siveke J; Billadeau DD; Ellenrieder V; Hessmann E
    Gastroenterology; 2015 May; 148(5):1024-1034.e9. PubMed ID: 25623042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling.
    De La O JP; Murtaugh LC
    Cell Cycle; 2009 Jun; 8(12):1860-4. PubMed ID: 19440048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro.
    Chen SJ; Chen YT; Zeng LJ; Zhang QB; Lian GD; Li JJ; Yang KG; Huang CM; Li YQ; Chu ZH; Huang KH
    Tumour Biol; 2016 Aug; 37(8):11299-309. PubMed ID: 26951514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
    Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA
    Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation.
    Dumartin L; Alrawashdeh W; Trabulo SM; Radon TP; Steiger K; Feakins RM; di Magliano MP; Heeschen C; Esposito I; Lemoine NR; Crnogorac-Jurcevic T
    Oncogene; 2017 Jun; 36(22):3094-3103. PubMed ID: 27941872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest.
    Morton JP; Jamieson NB; Karim SA; Athineos D; Ridgway RA; Nixon C; McKay CJ; Carter R; Brunton VG; Frame MC; Ashworth A; Oien KA; Evans TR; Sansom OJ
    Gastroenterology; 2010 Aug; 139(2):586-97, 597.e1-6. PubMed ID: 20452353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.
    Diersch S; Wirth M; Schneeweis C; Jörs S; Geisler F; Siveke JT; Rad R; Schmid RM; Saur D; Rustgi AK; Reichert M; Schneider G
    Oncogene; 2016 Jul; 35(29):3880-6. PubMed ID: 26592448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early requirement of Rac1 in a mouse model of pancreatic cancer.
    Heid I; Lubeseder-Martellato C; Sipos B; Mazur PK; Lesina M; Schmid RM; Siveke JT
    Gastroenterology; 2011 Aug; 141(2):719-30, 730.e1-7. PubMed ID: 21684285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer.
    Singh K; Pruski M; Bland R; Younes M; Guha S; Thosani N; Maitra A; Cash BD; McAllister F; Logsdon CD; Chang JT; Bailey-Lundberg JM
    Lab Invest; 2021 Feb; 101(2):177-192. PubMed ID: 33009500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.